Overview

Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis

Status:
Completed

Trial end date:
2015-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate pharmacodynamics (PD) in adult subjects with a diagnosis of Raynaud's Phenomenon secondary to Systemic Sclerosis (SSc).

Phase:

Phase 2

Details

Lead Sponsor:

NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)

Treatments:

Alprostadil